Verici Dx plc

VRCI

GB00BM8HZD43

Medical Equipment, Supplies & Distribution

Delayed London S.E. Other stock markets 11:00:49 17/03/2026 GMT			5-day change	1st Jan Change
0.5500 ^GBX	-4.35%		-4.35%	-24.14%

02-05	EARNINGS AND TRADING: React sales increase; Arcontech profit declines	AN
02-05	Verici Dx's Tutivia Added as In-network Test Under BCBS Deal	MT

Verici Dx plc Announces Revenue Results for the Year Ended 31 December 2025

Published on 02/05/2026 at 07:01 am GMT

S&P Capital IQ

VERICI DX PLC

-4.35%

Verici Dx plc announced revenue results for the year ended 31 December 2025. For the period, the company reported Total unaudited revenues of $3.8 million as compared to $3.3 million a year ago.

Latest news about Verici Dx plc

02-05	EARNINGS AND TRADING: React sales increase; Arcontech profit declines	AN
02-05	Verici Dx's Tutivia Added as In-network Test Under BCBS Deal	MT
02-05	Verici reports unaudited revenues of $3.8m for FY25	RE
02-05	Earnings Flash (VRCI.L) Verici Dx plc Reports FY25 Revenue $3.8M	MT
02-05	Verici Dx plc Announces Revenue Results for the Year Ended 31 December 2025	CI
11-12	Verici passes laboratory inspection by US accreditor	AN
11-12	AIM WINNERS & LOSERS: Quantum Blockchain launches new software version	AN
11-06	AIM WINNERS & LOSERS: Asiamet to sell project stake; Ethernity sinks	AN
11-06	Verici Dx plc Signs Provider Participation Agreement with Prime Health Services	CI
11-03	Northcoders contract wins; Verici Dx completes audit	AN
07/10/25	Verici Dx plc - Special Call
06/10/25	Verici Dx Onboards Nine New Transplant Centers for Tutivia Test in Q3	MT
06/10/25	Verici Dx shares jump as posts progress on Tutivia adoption	AN
06/10/25	AIM WINNERS & LOSERS: HSS Hire swings to loss, inks Speedy Hire deal	AN
06/10/25	Verici Dx plc Announces Board Changes, Effective October 6, 2025	CI

Verici Dx plc is an immuno-diagnostics development company. The Company develops a suite of tests forming a kidney transplant platform for personalized patient and organ response risk to assist clinicians in medical management for improved patient outcomes. The principal activity is the development of prognostic and diagnostic tests for kidney transplant patients. The Company's kidney transplant assays use sequencing that defines a personalized risk-profile of each patient over the course of the transplant journey. The Company develops tests to understand how a patient is responding to organ transplants. Its products include Clarava, Tuteva and Protega. Clarava is a pre-transplant prognosis for the risk of early acute rejection (EAR). Tuteva is a post-transplant diagnostic focused upon acute cellular rejection (ACR), including subclinical rejection. Protega is a liquid biopsy that aims to predict the risk of fibrosis and long-term graft failure. Its subsidiary is Verici Dx Inc.

Employees

Sector

Medical Equipment, Supplies & Distribution

More about the company